EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 191 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at Work (PSR) as a Critical Opportunity to Protect the Wellbeing of the Cancer... FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced MOST POPULAR On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... December 13, 2019 Study Suggests Statins May Help Keep Breast Cancer from Spreading to... June 24, 2020 Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer May 24, 2019 Load more HOT NEWS A new IARC live webinar on evidence in primary cancer prevention FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer Keeping A Jasmine Plant In Your Room Reduces Anxiety, Panic Attacks... News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and...
